This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Foley J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders 39: Apr 2020. Available from: URL: http://doi.org/10.1016/j.msard.2019.101863